Physician profile
Marie Sighe-Nzokou
NPI 1699497834
$15,663.00
in general payments reported to CMS, 2019-2025
29 companies · $5,196 in 2025
The $5,196 reported for 2025 was more than what 99% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $224 · 2023: $4,051 · 2024: $6,192 · 2025: $5,196.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Consulting Fee: $1,560 · Education: $481 · Travel and Lodging: $93.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,304.53 |
| Consulting Fee | $1,560.00 |
| Education | $480.56 |
| Travel and Lodging | $93.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $2,949.22 | 2023-2025 | Bimzelx, Cimzia |
| Janssen Biotech, INC. | $2,758.59 | 2022-2025 | Tremfya, Simponi Aria, Simponi |
| Amgen INC. | $2,383.03 | 2023-2025 | Evenity, Tavneos, Otezla |
| Abbvie INC. | $2,352.52 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $1,087.45 | 2023-2025 | |
| Astrazeneca Pharmaceuticals Lp | $863.59 | 2022-2025 | Saphnelo |
| Ani Pharmaceuticals, INC. | $487.20 | 2023-2025 | Purified Cortrophin Gel |
| United Therapeutics Corporation | $369.26 | 2023-2025 | Tyvaso |
| Mallinckrodt Hospital Products INC. | $362.68 | 2023-2025 | Acthar |
| E.R. Squibb & Sons, L.L.C. | $276.81 | 2023-2025 | Orencia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $263.59 | 2022-2024 | Ofev, Cyltezo |
| Sandoz INC. | $157.34 | 2023-2025 | Hyrimoz, Jubbonti |
| Janssen Scientific Affairs, LLC | $154.74 | 2025 | Tremfya |
| Genzyme Corporation | $136.36 | 2023-2025 | |
| Alexion Pharmaceuticals, INC. | $124.44 | 2023-2025 | Strensiq, Ultomiris |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $121.01 | 2023-2025 | Renflexis, Hadlima |
| Aurinia Pharma U.S., INC. | $116.38 | 2023 | Lupkynis |
| Lilly USA, LLC | $114.30 | 2023-2025 | Taltz, Zepbound |
| Actelion Pharmaceuticals US, INC. | $102.13 | 2023-2025 | Opsumit, Uptravi |
| Radius Health, INC. | $98.57 | 2023-2024 | Tymlos |
| Horizon Therapeutics Plc | $90.85 | 2023 | Krystexxa |
| Alvogen INC | $70.88 | 2022-2025 | Teriparatide |
| Genentech USA, INC. | $59.08 | 2025 | Actemra, Gazyva |
| Fresenius Kabi USA, LLC | $55.18 | 2025 | |
| Sobi, INC | $34.34 | 2022-2023 | |
| Alnylam Pharmaceuticals INC. | $25.26 | 2025 | Givlaari |
| Kyowa Kirin, INC. | $18.60 | 2025 | |
| Mylan Institutional INC. | $15.39 | 2023 | Hulio |
| Hospira, INC. | $14.21 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marie Sighe-Nzokou listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.